{"filings":[{"id":2189476,"accession_number":"0001193125-26-344594","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-08-11T20:05:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.","Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; topline interim data expected 1H 2027.","TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients as of Aug 2026 cutoff.","Completed $230M follow-on offering; cash and equivalents $455.4M as of June 30, 2026, runway into 2H 2028.","Expanded Catalent partnership for commercial manufacturing; appointed Mike Johannesen as Chief Legal Officer in June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1277437,"accession_number":"0001193125-26-282855","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-06-25T20:26:17+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.","Net proceeds ~$187.4M; up to ~$215.6M if underwriters exercise 5M over-allotment option.","Underwriters: Jefferies, Goldman Sachs, Piper Sandler, Cantor; Baird as lead manager.","Company expects cash runway into second half of 2028.","Offering expected to close June 26, 2026; dilution to existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1177356,"accession_number":"0001193125-26-276738","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-06-22T12:14:24+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Taysha completes REVEAL pivotal trial dosing; longer-term data shows durable functional gains in Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.","100% of 12 REVEAL Part A patients gained/regained ≥1 developmental milestone by 12 months post-TSHA-102.","No treatment-related SAEs or DLTs across 29 patients dosed as of June 2026 cutoff.","310 total functional gains observed ≥12 months post-treatment (~26 per patient) across core disease domains.","ASPIRE trial enrollment exceeded; expects to dose 4th patient in July 2026; safety data to support BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805841,"accession_number":"0001193125-26-253478","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-06-02T20:05:28+00:00","items":["5.07"],"status":"ready","headline":"Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.","Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.","Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.","Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.","Approximately 84.86% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95619,"accession_number":"0001193125-26-207633","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.","Cash $276.6M; company expects runway into 2028.","FDA reaffirmed alignment on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential 6-month interim submission.","Dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion; no treatment-related SAEs or DLTs to date.","BLA-enabling PPQ campaign initiated April 2026; completion expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108812,"accession_number":"0001193125-26-115177","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.","Cash $319.8M as of Dec 31, 2025; raised $50M via ATM in Q4; expects funding into 2028.","Dosed multiple Rett patients in REVEAL pivotal trial; enrollment advancing, on track to complete dosing in Q2 2026.","FDA cleared ASPIRE trial in patients aged 2 to <4 yrs; alignment on CMC and data pooling for BLA submission.","TSHA-102 generally well tolerated; no treatment-related SAEs or DLTs as of March 2026 data cutoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125260,"accession_number":"0001193125-25-263543","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.","First patient dosing in REVEAL pivotal trial scheduled Q4 2025; enrollment to continue at multiple sites.","Regained full unencumbered rights to TSHA-102 after Astellas option agreement expired in October 2025.","Q3 2025 net loss $32.7M ($0.09/share); R&D $25.7M; cash $297.3M expected to fund operations into 2028.","David McNinch appointed Chief Commercial Officer in September 2025; TSHA-102 generally well tolerated with no treatment-related SAEs in 12 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125259,"accession_number":"0001193125-25-241415","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.","TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.","REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.","Unencumbered rights enable full strategic flexibility and optionality for Taysha."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125258,"accession_number":"0001193125-25-235212","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.","22 developmental milestones gained across domains of communication, fine motor, gross motor.","Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).","Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.","Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125257,"accession_number":"0001193125-25-227505","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy designation for TSHA-102 in Rett syndrome; pivotal trial protocol finalized","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Breakthrough Therapy designation for TSHA-102 based on Part A data from 12 patients showing 100% response rate on milestone gain.","FDA alignment finalized on REVEAL pivotal trial protocol and SAP; 6-month interim analysis could expedite BLA by at least two quarters.","Pivotal trial to enroll 15 females aged 6-22 with primary endpoint of milestone gain; enrollment on track for Q4 2025.","Clinical data also showed dose-dependent improvements on R-MBA and CGI-I; safety generally well-tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141991,"accession_number":"0001193125-25-178504","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $312.8M after $230M follow-on offering; runway extended into 2028.","Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.","REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.","100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.","New supplemental clinical data from Part A expected in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":4288000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159941,"accession_number":"0001193125-25-133745","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Taysha Gene Therapies shareholders approve authorized share increase to 700M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.","Directors Phillip B. Donenberg and Sukumar Nagendran elected with 114.3M and 123.3M votes for, respectively.","Deloitte & Touche ratified as independent auditor for FY2025; 179.4M votes for.","Annual meeting turnout: 179.6M shares (~87%) of 205.1M outstanding represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159940,"accession_number":"0001193125-25-130709","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.","Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.","TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.","FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.","Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159937,"accession_number":"0001193125-25-129849","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K/A","filed_at":"2025-05-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Taysha reports FDA-aligned pivotal trial for TSHA-102; 100% of Part A patients gained milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA aligned on single-arm pivotal Part B trial (N=15) for TSHA-102 in Rett syndrome patients ≥6 years; primary endpoint: developmental milestone gain/regain.","Part A: 100% (10/10) of patients aged 6-21 gained ≥1 milestone; high dose showed faster and deeper effects vs low dose.","Natural history data (~1,100 patients) showed ~0% likelihood of milestone gain/regain after age 6, supporting trial design.","No treatment-related SAEs or DLTs; all related AEs mild-to-moderate across 12 patients.","Company suspended $100M ATM prospectus; Sales Agreement remains in effect; new prospectus required for future sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159939,"accession_number":"0001193125-25-129494","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies Announces FDA Alignment on Pivotal Part B Trial Design for TSHA-102 in Rett Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["100% of 10 patients in Part A gained/regained ≥1 developmental milestone post-TSHA-102, with ~0% likelihood from natural history data.","FDA supports single-arm open-label pivotal trial (N=15) with primary endpoint of developmental milestone gain/regain in patients ≥6 years.","High dose outperformed low dose, with dose-dependent effects deepening over time; no treatment-related SAEs or DLTs.","Analysis of IRSF natural history study (N~1100) showed patients ≥6 years in developmental plateau, <6.7% likelihood of milestone gain.","Company expects to submit protocol this quarter and initiate pivotal trial in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159938,"accession_number":"0001193125-25-120329","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha secures FDA alignment on TSHA-102 pivotal trial design; Q1 net loss $21.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA alignment on pivotal Part B trial design; IND amendment with protocol/SAP expected Q2 2025, potentially expediting registration.","TSHA-102 well tolerated: no treatment-related SAEs or DLTs in 10 patients (6 high dose, 4 low dose) as of April 10, 2025 cutoff.","Q1 2025 net loss $21.5M ($0.08/sh) vs $24.1M ($0.10/sh) in Q1 2024; cash $116.6M expected into Q4 2026.","R&D expenses $15.6M, down from $20.7M YoY due to lower manufacturing costs; G&A expenses $8.2M, up from $7.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178279,"accession_number":"0001193125-25-035882","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.","TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.","Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.","R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).","Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":8333000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194927,"accession_number":"0001193125-24-257205","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.","High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.","FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.","FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.","Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":6311000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211221,"accession_number":"0001193125-24-198392","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.","Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.","TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.","High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":4523000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229773,"accession_number":"0001193125-24-169191","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.","Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).","Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.","Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.","Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229772,"accession_number":"0001193125-24-168479","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Taysha launches $75M public offering; reports positive clinical data in Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.","TSHA-102 in Rett syndrome shows sustained improvements in motor, hand function, and seizure reduction in two adult patients at 52 and 36 weeks.","IDMC approved dose escalation to cohort 2; first high-dose patient dosed in Q2 2024; initial data from cohort 2 expected H2 2024.","Received RMAT designation from FDA for TSHA-102 in April 2024, providing expedited development pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229771,"accession_number":"0001193125-24-163050","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.","Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.","Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.","IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.","TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229770,"accession_number":"0001193125-24-150323","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elect Sean Stalfort and Alison Long as directors until 2027.","Deloitte & Touche LLP ratified as independent auditor for FY2024.","Approximately 80% of outstanding shares (149.6M of 187M) were represented at the meeting.","Director votes: Stalfort 131.8M for, 287.6K withheld; Long 132.0M for, 77.5K withheld.","Auditor ratification: 149.5M for, 60.4K against, 100.5K abstained; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229769,"accession_number":"0001193125-24-138253","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.","FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.","Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.","Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.","Cash $124M; expects to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3411000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248264,"accession_number":"0001193125-24-071321","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.","Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.","Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.","TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.","IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248263,"accession_number":"0001193125-24-005637","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.","MHRA authorized UK CTA for TSHA-102 in pediatric patients, expanding REVEAL into the UK.","Initial safety and efficacy data for cohort one (low dose, n=3) expected in mid-2024.","TSHA-102 uses miRARE technology to mediate MECP2 expression on a cell-by-cell basis.","TSHA-102 also has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265757,"accession_number":"0001193125-23-299942","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).","President & Head of R&D Sukumar Nagendran receives 863,617 options and 863,617 RSUs.","CFO Kamran Alam receives 590,413 options and 590,413 RSUs.","Options vest 25% at 1 year, then monthly over 3 years; RSUs vest equally over 4 years.","Board adopted 2023 Inducement Plan reserving 4M shares for new-hire grants under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265756,"accession_number":"0001193125-23-277914","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Taysha Gene Therapies stockholders approve doubling authorized common stock to 400M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Nov 15, 2023: 72.16% of shares represented; amendment passed with 133,386,292 votes for.","Authorized shares increased from 200,000,000 to 400,000,000 via Certificate of Amendment filed with Delaware.","Only 1,370,285 votes against and 157,132 abstained out of 134,913,709 shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265755,"accession_number":"0001193125-23-277165","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.","Cash and cash equivalents $164.3M; runway extended into 2026 via new loan with Trinity Capital (no financial covenants or warrants).","TSHA-102 first two adult patients: well-tolerated, no SAEs; sustained improvements in autonomic, motor, socialization functions at week 12 (patient 1) and week 4 (patient 2).","IDMC cleared dosing of third adult patient; low-dose cohort completion and first U.S. pediatric dosing expected Q1 2024.","R&D expenses $11.8M (down from $16.8M YoY) due to lower headcount and licensing fees, partially offset by clinical trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":11847000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265754,"accession_number":"0001193125-23-268173","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha Gene Therapies appoints Alison Long to Board; Kathleen Reape resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen Reape resigns from Board effective Nov 1, 2023, per employer governance rules; no disagreement with company.","Alison Long appointed as Class I director effective Nov 1, 2023, and chair of Clinical and Science Committee.","Long also appointed to Compensation and Nominating & Corporate Governance Committees.","Long receives initial stock option for 43,800 shares vesting over 36 months plus annual retainers ($35k director, extra committee fees).","Long currently CMO of Flightpath Biosciences (consulting) and Clinical Lead of Enigma Biomedical Group; previously CMO at Anokion, Kaleido."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282984,"accession_number":"0001193125-23-241943","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.","Clinical data from both low-dose adult patients to be reported on mid-November earnings call after IDMC review.","Enrollment completion in low-dose cohort (third patient) expected Q4 2023.","First pediatric patient dosing expected Q1 2024; FDA cleared pediatric IND.","UK MHRA CTA for pediatric patients submitted; feedback expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282983,"accession_number":"0001193125-23-237632","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.","Astellas Gene Therapies declined its option to license TSHA-120.","Cash runway extended into Q4 2025 by prioritizing TSHA-102 for Rett syndrome.","Ongoing REVEAL Phase 1/2 trial for TSHA-102 in adults; pediatric trial planned.","Taysha to pursue external strategic options for TSHA-120 to enable further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282982,"accession_number":"0001193125-23-222964","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Taysha Gene Therapies regains compliance with Nasdaq listing rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 28, 2023, confirming compliance with minimum Market Value of Listed Securities of $50M.","Received separate Nasdaq notice on same date confirming compliance with minimum bid price of $1.00 per share.","Both compliance matters are now closed, removing delisting risk for TSHA on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282981,"accession_number":"0001193125-23-219580","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies receives FDA Fast Track Designation for TSHA-102 in Rett syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.","TSHA-102 also holds FDA Orphan Drug and Rare Pediatric Disease designations plus EU Orphan Drug.","Phase 1/2 REVEAL adult trial ongoing in Canada; second adult patient expected in current quarter.","FDA cleared IND for pediatric patients; first pediatric dose expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282980,"accession_number":"0001193125-23-211456","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Taysha raises $150M PIPE; first Rett patient data shows clinical improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $150M from PIPE: 122.4M shares at $0.90/share and 44.3M pre-funded warrants.","Q2 2023 net loss $24.6M ($0.38/sh); cash $45.1M at June 30; PIPE extends runway into Q3 2025.","First adult Rett patient dosed in REVEAL trial: TSHA-102 well-tolerated, no SAEs at 6 weeks.","At 4 weeks, CGI-I score of 2 (much improved), RSBQ improved 23 points, patient gained ability to sit unassisted and hold objects.","FDA cleared IND for TSHA-102 in pediatric Rett; CTA submitted to UK MHRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282979,"accession_number":"0001193125-23-203836","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Taysha Gene Therapies receives Nasdaq notice for non-compliance with MVLS minimum $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received written notice from Nasdaq on Aug 3, 2023 for failing to meet $50M minimum MVLS requirement.","Has until Jan 30, 2024 to regain compliance by closing at $50M+ for 10 consecutive business days.","Common stock continues trading on Nasdaq Global Select under TSHA; may consider transfer to Cap Market.","Company intends to monitor MVLS and explore available options; no immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282978,"accession_number":"0001193125-23-198580","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.","Dosing of second patient expected in Q3 2023.","Initial clinical update on first patient planned for Q2 2023 earnings call in mid-August.","TSHA-102 is an AAV-based gene therapy for Rett syndrome due to MECP2 loss-of-function mutation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302339,"accession_number":"0001193125-23-176864","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Taysha reports new TSHA-120 data analysis supports FDA path; TSHA-102 first patient dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New TSHA-120 analysis shows 99% probability of slowing disease progression on mFARS and MFM32 Domain 3; FDA meeting expected Q3 2023.","First adult patient with Rett syndrome dosed with TSHA-102 in REVEAL Phase 1/2 trial; safety/efficacy update expected early Q3 2023.","CTA submission for TSHA-102 in pediatric Rett patients in UK mid-2023; IND submission to FDA H2 2023.","Over seven years of safety data support TSHA-120; DPM using natural history data supports external control for regulatory path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302338,"accession_number":"0001193125-23-173983","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Taysha stockholders approve reverse stock split and authorized share reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized with ratio range of 1:5 to 1:20; 43.1M for, 10.5M against.","Authorized shares reduction (formula based on split ratio) approved: 43.3M for, 10.2M against.","Both directors elected: Sean P. Nolan (35.6M for) and Laura Sepp-Lorenzino (33.6M for).","Ratification of Deloitte as auditor: 53.5M for, 51k against.","Broker non-votes of 14.3M on director elections; no broker non-votes on other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302337,"accession_number":"0001193125-23-172678","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha regains Nasdaq independence compliance; Manning resigns, Stalfort appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Manning resigned from board effective June 20, 2023 to enable compliance with Nasdaq Rule 5605(b)(1); remains as non-voting observer.","Sean Stalfort appointed as independent Class I director, chair of Nominating/Governance Committee, and member of Compensation Committee.","Stalfort granted option for 43,800 shares at closing price, vesting over 36 months; annual retainer $35k plus committee fees.","Majority of board now independent; company has regained compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302336,"accession_number":"0001193125-23-161593","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.","Awards tied to clinical, regulatory, and corporate milestones by Dec 31, 2023; vest over 3 years.","Board revised director compensation: initial equity grant set at 43,800 shares; annual at 36,200 shares.","Options under 2020 Stock Incentive Plan; intended to strengthen pay-for-performance alignment.","No departure reported; grants are one-time performance-based equity incentives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302335,"accession_number":"0001193125-23-160348","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha doses first patient with TSHA-102 in Phase 1/2 REVEAL trial for Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First adult patient received TSHA-102, an AAV9 gene therapy using miRARE technology to regulate MECP2.","Phase 1/2 REVEAL trial: open-label, dose-escalation (5x10^14 vg then 1x10^15 vg) and dose-expansion in adult females.","Initial safety data from first patient expected at R&D Day on June 28, 2023.","Study conducted at CHU Sainte-Justine in Montreal, Canada; independent data monitoring committee will review safety at ~6 weeks.","First time a gene therapy is evaluated clinically for Rett syndrome, per Taysha management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302334,"accession_number":"0001193125-23-148827","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha TSHA-102 data: safe in wild-type mice, extends survival >4x in Rett model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New wild-type mouse data: TSHA-102 showed no toxicity or survival reduction over 36 weeks, no impact on neurobehavioral function.","In Mecp2–/Y knockout mice, TSHA-102 led to 47% survival at 36 weeks vs median 8.1 weeks in vehicle group (>4-fold extension, p<0.0001).","TSHA-102 significantly delayed onset of severe Rett phenotypes: severe clasping from ~7 to 21 weeks, abnormal gait from ~8 to 20 weeks.","Dosing of first adult patient in Phase 1/2 REVEAL trial expected Q2 2023; initial safety data anticipated Q2 2023.","TSHA-102 uses miRARE technology to regulate MeCP2 expression, addressing risks of both under- and overexpression in mosaic X-chromosome silencing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302333,"accession_number":"0001193125-23-145197","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.","Initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023.","Net loss for Q1 2023 was $17.6M ($0.28 per share) vs. $50.3M ($1.32 per share) in Q1 2022.","Cash and equivalents $63.4M as of March 31, 2023; expected to fund operations into Q1 2024.","FDA meeting request for TSHA-120 (GAN) regulatory path expected Q2 2023; meeting anticipated Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302332,"accession_number":"0001193125-23-122129","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Taysha Gene Therapies receives Nasdaq bid price deficiency notice; board changes announced","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 25, 2023 for minimum bid price below $1.00 for 30 consecutive days.","Has 180 days until October 23, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for additional 180-day grace period; failure could lead to delisting.","Director Kathleen Reape resigned effective Nov 1, 2023 due to employer guidelines; Board to appoint successor.","Board reconstituted with six directors; Reape moves from Class III to Class I to allow shareholder vote in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322007,"accession_number":"0001193125-23-082174","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.","Cash $87.9M at 12/31/22; expected to fund operations into Q1 2024.","TSHA-102: screening started for REVEAL trial; first adult dosing H1 2023; initial safety data expected H1 2023.","TSHA-120: FDA suggests alternative trial designs; formal meeting request planned Q2 2023.","Non-cash impairment charge of $36.4M in Q4 2022 for NC manufacturing facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322004,"accession_number":"0001193125-23-064669","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K/A","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.","Severance includes salary continuation for 12 months at his base salary as of separation date.","Also includes COBRA premium payments until Dec 31, 2023 or earlier if new coverage.","Compensation Committee awarded 251,296 vested RSUs replacing a canceled option of 199,500 shares for 2021 performance bonus.","Session also resigned from Board on March 2, 2023, not due to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322006,"accession_number":"0001193125-23-020343","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha receives FDA feedback on TSHA-120 GAN; sets Rett syndrome milestones for 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA acknowledged MFM32 as acceptable endpoint; recommended double-blind placebo-controlled design for TSHA-120 BLA.","Dosing of first adult Rett patient with TSHA-102 expected H1 2023; initial clinical data also in H1 2023.","CTA submission to UK MHRA for pediatric Rett syndrome expected mid-2023; IND to FDA planned H2 2023.","Operational, structural and personnel changes implemented following business review to enhance execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322005,"accession_number":"0001193125-23-010947","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha Gene Therapies CMO Suyash Prasad departs effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Suyash Prasad separated from Taysha on Jan 12, 2023 by mutual agreement.","Separation agreement terms not yet finalized; company to file further details later.","No replacement named; CFO signed the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322003,"accession_number":"0001193125-23-003537","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K/A","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.","Nolan receives option for 1,106,131 shares; 25% vests Dec 16, 2023, remainder monthly over 36 months.","Sukumar Nagendran appointed President & Head of R&D; base $565K, bonus target 50%, option for 790,093 shares with same vesting.","Severance: Nolan gets 18 months salary + 150% target bonus; Nagendran 15 months + 100% target bonus upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-06T23:59:59+00:00|322003"}